1. Щукин Ю.В., Рябов А.Е. Хроническая ишемическая болезнь сердца в пожилом и старческом возрасте. Пособие для врачей. Самара: Волга-Бизнес, 2008; с. 44.
2. Косарев В.В., Бабанов С.А. Клиническая фармакология лекарственных средств, применяемых при сердечно-сосудистых заболеваниях. Самара: Офорт, 2010; с. 140
3. Косарев В.В., Бабанов С.А., Астахова А.В. Фармакология и лекарственная терапия. Под ред. В.К.Лепахина. М.: Эксмо, 2009.
4. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск. тер. и проф. 2005; 4 (1): 4–9.
5. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in Multiple risk factor intervention trail research group. Arch Intern Med 1992; 152: 1490–500.
6. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176–80.
7. Simes RJ, Marschner IC, Hunt D et al. Relationship between lipid 7. levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Heart disease (LIPID) Trail: to what extent is the reduction in coronary events with pravastatin explain by on-study lipid levels. Circulation 2002; 105: 1162–9.
8. Российские рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза». Секция атеросклероза ВНОК. Кардиоваск. тер. и профилакт. 2004; 2(прил.): 36.
9. The Cholesterol and Recurrent Events Trail Investigators. The effect of pravastatin on coronary events after myocardial infarction in patientd with average cholesterol levels. N Engl J Med 1998; 335: 1001–9.
10. Athyros. VG, Papageorgiou AA, Mercouris BR. The Greak Atorvastatin and acoranary heart disease Evaluation (GREECE) Study. Curr Med Res Opin 2002; 18: 220–8.
11. Serruys PW, de Feuter P, Macaya C et al. Intervention Prevention. Study (LIPID) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trail. JAMA 2002; 287: 3215–2.
12. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7.
13. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group, (1998). Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA 279: 1615–22.
14. Kleemann R., Kooistra T. HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol. Curr Drug Targets Cardiovasc Haematol Disord. 2005; 5 (6): 441–53.
15. Marchioli R., Investigators G.T. Beneficial effects of statins. The Lancet 1996; 348: 1582.
16. Grines CL. The role of statins in reversing atherosclerosis: what the latest regression studies show. J Interv Cardiol 2006; 19 (1): 3–9.
17. Аронов Д.М. Плеотропные эффекты статинов. РМЖ. 2001; 9: 13–4.
18. Schwartz GG, Ollson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACLE) study Investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial. JAMA 2001; 285 (13): 1711–8.
19. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
20. Collhoun HM, Betteridge DJ, Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685–96.
21. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. (ASCOT–LLA): a Multicentre controlled lipid-lowering trial. Lancet 2003; 361: 1149–58.
22. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425–35. Epub 2005 Mar 8.
23. Pedersen TR., Faergeman O, Kastelein JJ et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437–45.
24. Nissen SE, Tuzcu EM, Schoenhagen P et al REVERSAL Investigators. Effect of intensive compared with moderate lipid–lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071–80.
25. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582–7.
26.  Andrews TC, Ballantyne CV, Hsia JA et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med;111 (3);185–91.13.
27. Karalis DG., Ross AM., Vacari RM. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002; 89 (6): 667–71.
28. Jones PH., McKenney JM., Karalis DG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.Evide. Based Cardiovasc Med 2005; 9 (2): 98–101.
29. Schrott H, Fereshetian AG , Knopp RH et al. A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998; 3 (2): 119–24.
30. Okazaki S, Yokoyama T, Miyauchi K et al. Early statin treatment in patients with acute coronary syndrome. Circulation 2004; 110: 1061–8.
31. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
32. The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Cerebrovasc Dis 2003; 16: 389–95.
33. Клиническая фармакология. Под ред. В.Г.Кукеса. М.: ГЭОТАР-Медиа, 2008; с. 1056.

В.В.Косарев, С.А.Бабанов 

ГОУ ВПО Самарский государственный медицинский университет